Article Versions Notes

Servais L, Lair LL, Connolly AM, Byrne BJ, Chen KS, Coric V, Qureshi I, Durham S, Campbell DJ, Maclaine G, et al. Taldefgrobep Alfa and the Phase 3 RESILIENT Trial in Spinal Muscular Atrophy. International Journal of Molecular Sciences. 2024; 25(19):10273. https://doi.org/10.3390/ijms251910273

Servais, Laurent, Lindsey Lee Lair, Anne M. Connolly, Barry J. Byrne, Karen S. Chen, Vlad Coric, Irfan Qureshi, Susan Durham, Daniel J. Campbell, Grant Maclaine, and et al. 2024. "Taldefgrobep Alfa and the Phase 3 RESILIENT Trial in Spinal Muscular Atrophy" International Journal of Molecular Sciences 25, no. 19: 10273. https://doi.org/10.3390/ijms251910273

Servais, L., Lair, L. L., Connolly, A. M., Byrne, B. J., Chen, K. S., Coric, V., Qureshi, I., Durham, S., Campbell, D. J., Maclaine, G., Marin, J., & Bechtold, C. (2024). Taldefgrobep Alfa and the Phase 3 RESILIENT Trial in Spinal Muscular Atrophy. International Journal of Molecular Sciences, 25(19), 10273. https://doi.org/10.3390/ijms251910273